Eli Lilly Q3 2026: Tirzepatide Fuels a Massive Guidance Raise
Eli Lilly reported Q3 2026 revenue of $24.40B, up 39% YoY, and raised full-year guidance to $91B-$92B. Tirzepatide (Mounjaro, Zepbound) drove growth, with volume up 53% YoY. The company absorbed $4.18B in R&D charges but saw gains from Jardiance milestones. FDA approvals for Onswik and Inluriyo were also announced.
How this was made
The 30-second read
Why it matters
The market-relevant change is the company’s own guidance raise alongside Q3 beats, plus additional pipeline regulatory milestones and a stated next Phase 3 catalyst in Q4 2026.
Market read
A quantified guidance increase tied to tirzepatide volume growth is the primary driver for near-term repricing, with pipeline approvals and upcoming Phase 3 timing adding incremental catalyst visibility.
What to watch
The article notes no further Jardiance milestones remain and that oncology, immunology, and neuroscience doubled, but it does not quantify sustainability or margins by segment, leaving room for skepticism on how much of the upside is mix and one-time items.
Background
The piece frames Lilly’s Q3 2026 performance as being powered by tirzepatide (Mounjaro for diabetes, Zepbound for obesity), with international demand and China reimbursement dynamics playing a key role.
Ticker impact
Eli Lilly raised full-year 2026 revenue guidance to $91B-$92B after Q3 revenue and adjusted EPS beats, driven by tirzepatide demand.
Likely positive bias as the market re-rates Lilly on higher 2026 revenue and EPS/performance-margin outlook tied to Mounjaro and Zepbound demand.
The article provides specific, company-issued Q3 results and a quantified full-year guidance increase, with clear drivers (tirzepatide volume growth and expanded coverage) plus identifiable offsets (China pricing pressure, acquisition-related charges).
Market effects
Reinforces bullish read-through for GLP-1 and obesity franchise demand, while highlighting that reimbursement-driven price compression can coexist with volume growth.
China reimbursement inclusion is framed as boosting demand but pressuring realized prices, which may influence how investors model international GLP-1 economics.
Supports broader investor confidence in large-cap obesity/diabetes platforms and their ability to sustain growth while managing international pricing dynamics.
Counterpoint
The guidance raise may be partially offset by acquisition-related in-process R&D charges and China reimbursement-driven realized price pressure, which could make the earnings quality less durable than the headline growth suggests.
Key entities
- companyEli Lilly
Reported Q3 2026 revenue and adjusted EPS beats and raised full-year 2026 guidance, citing tirzepatide demand and expanded coverage.
- productTirzepatide (Mounjaro, Zepbound)
GLP-1/GIP agonist driving volume growth, with China reimbursement inclusion boosting demand but lowering realized prices.
- productOnswik
Once-weekly basal insulin referenced as receiving FDA approval in the quarter.
- productInluriyo (with Verzenio)
Referenced as receiving regulatory milestone in combination for a specific advanced breast cancer form.
- pipeline_programEloraTZP
Phase 3 trials beginning in Q4 2026 for a combination of eloralintide and tirzepatide.
